レブリミド®5mgカプセルを投与され、レブリミド治療を継続中または中止した骨髄異形成症候群患者における、骨髄異形成症候群から急性骨髄性白血病への形質転換の発生を分析する研究

基本情報

NCT ID

NCT02921815

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

84

治験依頼者名

Celgene

概要

To analyze the occurrence of transformation from myelodysplastic syndrome (MDS) to acute myeloid leukemia (hereinafter referred to as transformation from MDS to AML) in patients with myelodysplastic syndrome with a deletion 5q cytogenetic abnormality (hereinafter referred to as del(5q)MDS) who received Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) and who are continuing or no longer continuing Revlimid treatment. 1. Planned registration period This period started on the date of initial marketing of Revlimid and will end on the day when the appropriateness of enrollment is assessed for all del(5qMDS) patients in the all-case surveillance. 2. Planned surveillance period This period started on the date of initial marketing of Revlimid and will end 3 years after the last enrolled patient begins receiving Revlimid.

対象疾患

依頼者（Sponsor）

実施施設 (1)